뉴포리아테라퓨틱스(NEUP) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 9.05% | Shs Outstand | - | Perf Week | 16.67% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 40.29% | Insider Trans | - | Shs Float | 4.9M | Perf Month | -11.49% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.56 | Inst Own | 34.56% | Short Float | 0.31% | Perf Quarter | -23.61% |
| Income | - | P/S | - | EPS this Y | -1669.57% | Inst Trans | 6.11% | Short Ratio | 0.08 | Perf Half Y | -8.11% |
| Sales | - | P/B | 0.7 | EPS next 5Y | - | ROA | - | Short Interest | 0.02M | Perf YTD | -0.77% |
| Book/sh | 5.47 | P/C | 1.07 | EPS past 3/5Y | -17.62% -20.01% | ROE | - | 52W High | -82.01% ($21.40) | Perf Year | -54.71% |
| Cash/sh | 3.6 | P/FCF | - | Sales past 3/5Y | 334.17% 246.61% | ROIC | - | 52W Low | 20.69% ($3.19) | Perf 3Y | -83.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -15957.73% | Gross Margin | - | Volatility(W/M) | 8.29% 8.42% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.31 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.31 | EPS Q/Q | 92.44% | Profit Margin | - | RSI (14) | 50.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.31 | Sales Q/Q | -100% | SMA20 | 6.64% ($3.61) | Beta | 0.77 | Target Price | $7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/06/03 | SMA50 | -10.38% ($4.3) | Rel Volume | 1.05 | Prev Close | $3.64 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -22.08% ($4.94) | Avg Volume(3M) | 0.19M | Price | $3.85 |
| IPO | 2021/12/16 | Option/Short | No/Yes | Trades | 903 | Volume | 204,860 | Change | 5.77% |
Neuphoria Therapeutics Inc (NEUP) Investment Analysis
What kind of company is Neuphoria Therapeutics Inc?
🧠 Neuphoria Therapeutics () is a clinical-stage biotech developing oral anti-anxiety and neuropsychiatric therapies that target the α7 nicotinic receptor. Its lead candidate, BNC210, suffered a setback when it failed to meet the primary endpoint in the Phase 3 social anxiety disorder (SAD) trial, but the company is regrouping around the Phase 2b SYMPHONY trial in post-traumatic stress disorder (PTSD) and its Alzheimer's PAM partnership (MK-1167) with Merck (MRK), making it a small-cap neuroscience biotech play.
Learn more about Neuphoria Therapeutics Inc →Key Events
Is it profitable?
What's the outlook?
Did earnings meet expectations?
Is it growing?
Has the stock risen over the long term?
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current price $3.85 above the midline ($3.61). Normal upward flow. Inside the Ichimoku cloud (neutral).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
MACD -0.184 · Signal -0.259 · Hist 0.075. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
RSI 50.7 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 62.0.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Who owns it?
ETFs holding NEUP
How much does it pay in dividends?
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| NEUP This Stock | $20.8M | - | 0.7 ▲ | - | - | +5.8% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 뉴포리아테라퓨틱스(NEUP)?
뉴포리아테라퓨틱스(NEUP) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NEUP?
The market cap of NEUP is approximately $21M, ranking 5,252 within its sector.
What is the 52-week high and low for NEUP?
NEUP has recorded a 52-week high of $21.40 and a low of $3.19.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.